Sees FY23 adjusted EBITDA $180M-$200M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on EVH:
- Evolent Health Announces Fourth Quarter and Full Year 2022 Results
- Evolent Health price target raised to $59 from $57 at Cowen
- Centene completes divestiture of Magellan Specialty Health to Evolent Health
- Evolent Health jumps after announcing expansion of Humana pact
- Evolent Health price target raised to $51 from $44 at Piper Sandler